Form 4: Anika Therapeutics SVP Anne Nunes Reports Stock Transactions
SEC Form 4
Anne Nunes, SVP and Chief Operations Officer of Anika Therapeutics, reports the vesting of restricted stock units and associated tax withholding.
Summary
- On March 17, 2025, Anne Nunes, SVP, Chief Operations Officer of Anika Therapeutics, reported transactions involving common stock and restricted stock units (RSUs).
- 3,637 shares were acquired upon the vesting of RSUs, settled in shares.
- 1,068 shares were withheld by the issuer to satisfy tax obligations related to the RSU vesting at a price of $15.91.
- Following these transactions, Nunes directly owns 20,654 shares of common stock.
- Nunes also holds 7,275 RSUs after the reported transactions.
- 20,761 RSUs were granted on March 14, 2025, vesting in three equal annual installments beginning March 14, 2026.
- 4,650 performance-based phantom RSUs were granted on March 14, 2025, cliff vesting on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't contain overtly positive or negative information, reflecting a neutral sentiment.
Positives
- The vesting of RSUs indicates a form of compensation and alignment of the executive's interests with the company's performance.
Future Outlook
The document outlines future vesting schedules for RSUs, indicating continued equity-based compensation for the reporting person.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the equity-based compensation structure at Anika Therapeutics.
Comparison to Industry Standards
- Equity compensation, including RSUs, is a standard practice in the biotechnology and pharmaceutical industries to incentivize executives and align their interests with shareholders.
- Companies like Zimmer Biomet and Stryker also utilize RSUs as part of their executive compensation packages.
- The vesting schedules and performance-based components are also common features in executive compensation plans within the industry.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation and stock ownership changes.
- Employees may view the vesting of RSUs as a positive sign of company performance and executive alignment.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of RSU grants and the trading day prior to RSU vesting, used for tax withholding price. |
| 03/15/2024 | Date of original RSU grant, first vesting installment. |
| 03/15/2025 | Date of RSU vesting that gave rise to tax withholding obligations. |
| 03/17/2025 | Date of reported transactions (RSU vesting and tax withholding). |
| 03/18/2025 | Date of Form 4 signature. |
| 03/14/2026 | First vesting date for 20,761 RSUs. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.